Abstract
In recent years Immune Check Point Inhibitors (ICIs) have played an integral role in the treatment of a wide variety of malignancies. Despite improvements in survival outcomes with immunotherapy, immune related Adverse Events (irAEs) are increasing in incidence
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
